A topical gel treatment derived from birch bark significantly speeds up wound healing compared with standard care in patients with epidermolysis bullosa (EB) lesions, according to the EASE trial presented at the EADV 2020 Conference — representing the first-ever treatment to show positive results for the rare skin disorder.
Treatment with apremilast led to significantly improvedpatient-reported quality of life (QoL) outcomes in patients with moderate-to-severe plaque psoriasis of the scalp, according to the STYLE* study presented at EADV 2020.
The efficacy of tildrakizumab in chronic moderate-to-severe* plaque psoriasis is maintained after 5 years of treatment, final pooled analyses of the phase III reSURFACE 1 and reSURFACE 2 trials showed.
The modified glutathione (GSH-C4) with beta glycyrrhetic and azelaic acids cream is effective in the treatment of mild-to-moderate rosacea, with local tolerability consistent with other antirosacea medications, according to a study presented at the 29th Congress of the European Academy of Dermatology and Venereology (EADV 2020).
Levels of insulin resistance markers tend to be elevated in patients with acne vulgaris, supporting the association between acne vulgaris and insulin resistance, according to the results of a systematic review and meta-analysis.
INCB054707, an oral Janus kinase (JAK)1 inhibitor, shows promise in the treatment of moderate-to-severe hidradenitis suppurativa, reducing the abscess and inflammatory nodule count in addition to having an acceptable safety profile, according to data from two phase II trials.
The search for chronic hand eczema relief has led to two different Janus kinase (JAK) inhibitors, one topical and the other oral, with both performing well in phase IIb trials reported during the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress.
Patients with moderate-to-severe atopic dermatitis (AD) see clinical improvements in all body locations when treated with 100- or 200-mg doses of oral abrocitinib as compared with placebo, reports a new posthoc analysis presented at the recently concluded 2020 Virtual Congress of the European Academy of Dermatology and Venereology (EADV 2020).
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.